ASLAN Pharmaceuticals Limited (GTSM:6497) acquired global commercial rights for Varlitinib from Array BioPharma Inc. (NasdaqGM:ARRY) for approximately $130 million on January 3, 2018. As a part of consideration, ASLAN Pharmaceuticals will pay $12 million as upfront payment and further payment of up to $12 million within the next twelve months, together with up to $30 million of development and $75 million of commercial milestones as well as tiered low double-digit royalties as a percentage of net sales of varlitinib. ASLAN Pharmaceuticals Limited (GTSM:6497) completed the acquisition of global commercial rights for Varlitinib from Array BioPharma Inc. (NasdaqGM:ARRY) on January 3, 2018.